clinical trial · NCT07116746
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
GoutGouty ArthritisHyperuricemiaGout ChronicRefractory GoutUncontrolled GoutTophaceous GoutAR882 75 mgXOI Low DoseXOI High Dose
brief summary
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
started
Dec 3, 2025
primary completion
Jul 1, 2026
completion
Jan 1, 2027
last updated
Mar 2, 2026
official title
A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol